Teva's Copaxone Continues To Widen MS Market Lead In U.S.
Executive Summary
The multiple sclerosis market underwent a shake-out in 2008 when Teva's Copaxone managed to pull ahead of more established beta interferon therapies, including Biogen Idec's Avonex; the drug now holds 38 percent of the nearly $4.5 billion U.S. market
You may also be interested in...
Follow-on Biologic's Day Will Come - Post 2015, Teva Says
The generic giant acknowledges biogenerics as a major growth driver, but probably not before 2015.
The New Oral MS Drugs: The Challenges in Dislodging Biologics
Oral replacements for injectable drugs have long been an industry aspiration. The complex issues riased by the first oral MS drugs, as they try to take over territory pioneered by large molecules, reveal the challenges for companies pursuing other biologic-dominated businesses.
The New Oral MS Drugs: The Challenges in Dislodging Biologics
Oral replacements for injectable drugs have long been an industry aspiration. The complex issues riased by the first oral MS drugs, as they try to take over territory pioneered by large molecules, reveal the challenges for companies pursuing other biologic-dominated businesses.